First human tests begin for new Brain-Targeting drug
NCT ID NCT06007638
Summary
This early-stage study tested the safety of an experimental drug called LY3876602 in 74 healthy volunteers. Researchers gave participants increasing doses to see how their bodies reacted and measured how much drug reached both the bloodstream and spinal fluid. The main goal was to understand side effects and how the body processes the drug before testing it in people with medical conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON Early Phase Services, LLC
Groningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.